GSK’s follow-up to its severe asthma therapy Nucala has shown its value in a pair of phase 3 trials, reducing exacerbations compared to placebo with dosing once every six months. The company says new ...
Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...
Abstract: The dynamic wireless power transfer (DWPT) system with a two-phase bipolar narrow rail has the advantages of low power fluctuation and large lateral tolerance. Traditional two-phase systems ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results